ALK`s partner, Torii, gains paediatric approval for the house dust mite SLIT-tablet in Japan
(WorldNews Denmark)

Copenhagen, 2018-02-16 07:00 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its partner for Japan, Torii, has gained approval from the Japanese Ministry of Health, Labour and Welfare, to expand the use of ALK`s house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURETM to include paediatric allergic rhinitis patients. MITICURETM, which is sold by ALK as ODACTRATM in the USA and ACARIZAX® elsewhere in the world, has been available in Japan since 2015 for adults and adolescents aged 12-64 who suffer from HDM-induced allergic rhinitis. The product has also been...